Cargando…

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

Effective targeting of the human epidermal growth factor receptor 2 (HER2) has changed the natural history of HER2 overexpressing (HER2+) metastatic breast cancer. The initial success of trastuzumab improving time to progression and survival rates led to the clinical development of pertuzumab, ado-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, J C, Jhaveri, K, Esteva, F J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229628/ https://www.ncbi.nlm.nih.gov/pubmed/25025958 http://dx.doi.org/10.1038/bjc.2014.388

Ejemplares similares

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Advances in Alzheimer’s Disease Drug Development
por: Rafii, Michael S, et al.
Publicado: (2015)

Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
por: Sun, J, et al.
Publicado: (2017)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

(Hetero)aryl‐S(VI) Fluorides: Synthetic Development and Opportunities
por: Magre, Marc, et al.
Publicado: (2022)

Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor
por: Rao, Zhou-Zhou, et al.
Publicado: (2023)

Advances in drug therapy for systemic lupus erythematosus
por: Wallace, Daniel J
Publicado: (2010)

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
por: Attard, G, et al.
Publicado: (2006)

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
por: Lavaud, Pernelle, et al.
Publicado: (2014)

Nanopore Sequencing for Mycobacterium tuberculosis: a Critical Review of the Literature, New Developments, and Future Opportunities
por: Dippenaar, Anzaan, et al.
Publicado: (2022)

Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities
por: Manrai, Manish, et al.
Publicado: (2021)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

Developing Small‐Molecule Inhibitors of HECT‐Type Ubiquitin Ligases for Therapeutic Applications: Challenges and Opportunities
por: Chen, Dan, et al.
Publicado: (2018)

Halide Chemistry in Tin Perovskite Optoelectronics: Bottlenecks and Opportunities
por: Lanzetta, Luis, et al.
Publicado: (2022)

Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development
por: Abd-Rahman, Azrin N., et al.
Publicado: (2022)

A new paradigm for classifying and treating HER2‐positive breast cancer
por: He, Xuexin, et al.
Publicado: (2023)

Airborne Microalgae: Insights, Opportunities, and Challenges
por: Tesson, Sylvie V. M., et al.
Publicado: (2016)

Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities
por: Lippi, Giuseppe, et al.
Publicado: (2017)

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Role of liver transplantation in the management of colorectal liver metastases: Challenges and opportunities
por: Tasoudis, Panagiotis T, et al.
Publicado: (2021)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Advances in the Development of Antiviral Compounds for Rotavirus Infections
por: Tohmé, María Julieta, et al.
Publicado: (2021)

Consolidated bioprocessing for butanol production of cellulolytic Clostridia: development and optimization
por: Wen, Zhiqiang, et al.
Publicado: (2019)

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
por: Li, Yanbai, et al.
Publicado: (2023)

Clinical anticancer drug development: targeting the cyclin-dependent kinases
por: Benson, C, et al.
Publicado: (2005)

Genome editing of lactic acid bacteria: opportunities for food, feed, pharma and biotech
por: Börner, Rosa A, et al.
Publicado: (2018)

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
por: Gore, M E, et al.
Publicado: (2011)

Genetic tool development underpins recent advances in thermophilic whole‐cell biocatalysts
por: Taylor, M. P., et al.
Publicado: (2011)

Immunotherapy in triple-negative breast cancer: A literature review and new advances
por: Valencia, Guillermo Arturo, et al.
Publicado: (2022)

Strategies for discovery and improvement of enzyme function: state of the art and opportunities
por: Kaul, Praveen, et al.
Publicado: (2012)

Limitations and opportunities of non-invasive liver stiffness measurement in children
por: Engelmann, Guido, et al.
Publicado: (2017)

Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities
por: Jeong, Sehan, et al.
Publicado: (2023)

Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
por: Kanat, Ozkan, et al.
Publicado: (2018)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Multi-omics: Opportunities for research on mechanism of type 2 diabetes mellitus
por: Wang, Shuai, et al.
Publicado: (2021)

Flare of the silent pandemic in the era of the COVID-19 pandemic: Obstacles and opportunities
por: Rayan, Rehab A
Publicado: (2023)

Recent Advances in Catalytic Hydrosilylations: Developments beyond Traditional Platinum Catalysts
por: de Almeida, Leandro Duarte, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_37pvlt0vvsftd75rbjoolmqs3h